Association between Insulin Resistance and Lipid profile in a Sample of Iraqi Polycystic ovary syndrome Patients
DOI:
https://doi.org/10.24237/ASJ.02.02.756CKeywords:
Serum insulin, HOMA-IR, lipids profile, polycystic ovarian syndromeAbstract
A common metabolic disorder in women with polycystic ovarian syndrome (PCOS) is
dyslipidemia. Since insulin resistance is a major pathophysiology of PCOS, dyslipidemia in
PCOS-affected women may be consistent with that of insulin resistance. This study was planned
to determine insulin level in PCOS patients, and interpretation of Homeostatic Model
Assessment for Insulin Resistance (HOMA-IR) with lipid profile level. Fifty eight patients and
thirty controls were involved for this study. All subjects' lipid profiles, FBS, and insulin levels
were examined. Patients with PCOS had significantly higher serum insulin levels than the
healthy control group (p 0.05). Insulin resistance in PCOS is significantly higher than in healthy
controls. In PCOS patients, there is a negative connection between HOMA-IR and HDL-C.
HOMA-IR was found to positively correlate with TG and TC in the patient group where the
person coefficient values for (TG,TC and HDL-C) : 0.4486, 0.405 and 0.3109 respectively .
Conclusion: dyslipidemia and insulin resistance both lead to the development of atherosclerosis
in PCOS patients
References
M. C. Eiras, D. P. Pinheiro, K. A. M. Romcy, R. A. Ferriani, R. M. D. Reis, , C. L. M.
Furtado Polycystic ovary syndrome: the epigenetics behind the disease, Reproductive
Sciences, 1-15(2021)
S. R. Mahnoor, K. A. Awan, M. J. Iqbal, H. Munir, I. Saeed, Diet and lifestyle
modifications for effective management of polycystic ovarian syndrome (PCOS),
Journal of Food Biochemistry, 46(7), e14117(2022)
L. M. Howard, H. Khalifeh, Perinatal mental health: a review of progress and
challenges, World Psychiatry, 19(3), 313-327(2020)
H. G. Huddleston, A. Dokras, Diagnosis and treatment of polycystic ovary syndrome,
Jama, 327(3), 274-275(2022)
D. Rakic, V. Jakovljevic, N. Jovic, M. Bicanin Ilic, A. Dimitrijevic, T. Vulovic, J.
Joksimovic Jovic, The Potential of SGLT-2 Inhibitors in the Treatment of Polycystic
Ovary Syndrome: The Current Status and Future Perspectives. Biomedicines, 11(4),
(2023).
J. Zou, D. Wu, Y. Liu, Association of luteinizing hormone/choriogonadotropin receptor
gene polymorphisms with polycystic ovary syndrome risk: a meta-analysis, Gynecol
Endocrinol, 35(1),81–85(2019)
Hosseini, B. M. Razavi, M. Banach, H. Hosseinzadeh, Quercetin and metabolic
syndrome: A review. Phytotherapy Research, 35(10), 5352-5364(2021)
O. Osibogun, O. Ogunmoroti, E. D. Michos, Polycystic ovary syndrome and
cardiometabolic risk: opportunities for cardiovascular disease prevention, Trends in
cardiovascular medicine, 30(7), 399-404(2020)
C. X. Ma, X. N. Ma, C. H. Guan, Y. D. Li, D. Mauricio, S. B. Fu, Cardiovascular disease
in type 2 diabetes mellitus: progress toward personalized management, Cardiovascular
diabetology, 21(1), 74(2022)
Y. Xu, J. Qiao, Association of insulin resistance and elevated androgen levels with
Polycystic Ovarian Syndrome (PCOS): a review of literature, Journal of healthcare
engineering, (2022)
S. Singh, N. Pal, S. Shubham, D. K. Sarma, V. Verma, F. Marotta, M. Kumar, Polycystic
ovary syndrome: etiology, current management, and future therapeutics, Journal of
Clinical Medicine, 12(4), 1454(2023)
M. Dapas, A. Dunaif, Deconstructing a syndrome: genomic insights into PCOS causal
mechanisms and classification, Endocrine reviews, 43(6), 927-965(2022)
I. M. Vladu, M. Forțofoiu, D. Clenciu, M. C. Forțofoiu, R. Pădureanu, L. Radu, V.
Pădureanu, Insulin resistance quantified by the value of HOMA‑IR and cardiovascular
risk in patients with type 2 diabetes, Experimental and Therapeutic Medicine, 23(1),
-6(2022)
A. Gastaldelli, Measuring and estimating insulin resistance in clinical and research
settings, Obesity, 30(8), 1549-1563(2022)
D. R. Matthews, J. P. Hosker, A. S. Rudenski, B. A. Naylor, D. F. Treacher, R. C.
Turner, Homeostasis model assessment: insulin resistance and β-cell function from
fasting plasma glucose and insulin concentrations in man, Diabetologia, 28, 412-
(1985)
L. Shamai, E. Lurix, M. Shen, G. M. Novaro, S. Szomstein, R. Rosenthal, C. R. Asher,
Association of body mass index and lipid profiles: evaluation of a broad spectrum of
body mass index patients including the morbidly obese, Obesity surgery, 21(1), 42-
(2011)
W. B. Kannel, E. J. Lebauer, T. R. Dawber, Relation of body weight to development of
coronary heart disease: the Framingham Study, Circulation, 35, 734–44(1967)
B. V. Howard, W. C. Knowler, B. Vasquez, Plasma and lipoprotein cholesterol and
triglyceride in the Pima Indian population. Comparison of diabetics and nondiabetics,
Arterio- sclerosis, 4,462–71(1984)
M. Uusitupa, O. Siitonen, E. Voutilainen, Serum lipids and lipoproteins in newly
diagnosed non-insulin-dependent (type II) diabetic patients, with special reference to
factors influencing HDL- cholesterol and triglyceride levels. Diab Care., 9, 17–2(1986).
D. E. Laaksonen, M. Atalay, L. K. Niskanen, J. Mustonen, K. Chandan, T. A. Lakka,
M. I. Uusitupa, Aerobic exercise and the lipid profile in type 1 diabetic men: a
randomized controlled trial, Medicine & Science in Sports & Exercise, 32(9), 1541-
(2000)
S. Kuppusamy, G. K. Pal, S. Habeebullah, P. H. Ananthanarayanan, P. Pal, Association
of sympathovagal imbalance with cardiovascular risks in patients with polycystic ovary
syndrome, Endocrine research, 40(1), 37-43(2015)
R. S. Legro, S. A. Arslanian, D. A. Ehrmann, K. M. Hoeger, M. H. Murad, R. Pasquali,
C. K. Welt, Diagnosis and treatment of polycystic ovary syndrome: an endocrine society
clinical practice guideline, Reproductive Endocrinology, (20), 22-35(2014)
M. A. Ibarhim, M. S. Ahmeid, Metformin effects on vaspin levels and other parameters
in Iraqi polycystic ovarian women, EurAsian Journal of BioSciences, 14(2), 4493-
(2020)
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 CC BY 4.0
This work is licensed under a Creative Commons Attribution 4.0 International License.
